Shares of IQ-AI Ltd (LON: IQAI) today surged 8.47% after announcing that its Imaging Biometrics unit had launched an upgraded version of its IB Clinic software platform.
The company noted that the new release has multiple new enhancements of the platform requested by clients, as well as workflow efficiencies engineered by IB’s developers.
Michael Schmainda, Imaging Biometrics’ CEO, said: “This latest release further builds upon our proven track record of delivering scientifically proven advancements to clinicians. Ultimately, this release underscores IB's commitment to quality and helping clinicians improve care for their patients.”
Today’s news comes after the IQ-AI reported that its LSN (Liver Surface Nodularity) software application was approved for its CE Mark by European regulators earlier this week.
The CE mark confirmed that LSN, which is manufactured by IQ-AI subsidiary Imaging Biometrics, meets the essential requirements of the European Medical Devices Directive.
IQ-AI’s LSN software had earlier received 510(k) market clearance from the US Food and Drug Administration (FDA) giving the product access to the two most-prominent healthcare markets in the world.
The company continues to make significant progress in the different sectors in which it operates, given that it recently partnered with the Mayo Clinic to develop a brain lesion tracking platform.
IQ-AI shares had given up all their gains and were trading lower for the day at the time of writing.
IQ-AI share price
IQ-AI shares today surged 8.47% to trade at 16p having rallied from Wednesday’s closing price of 14.75p.